Ensemble Therapeutics Corporation to Present Data on IL-17A Inhibitors that are Novel, Oral Macrocycles Against Previously Undruggable Target
4/1/2013 10:03:11 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ensemble Therapeutics today announced that preclinical data showing the advantages of its Ensemblins, novel macrocyclic compounds against challenging drug targets, will be presented at the 245th American Chemical Society (ACS) National Meeting being held April 7-11, 2013 in New Orleans, LA. In particular, the presentation will highlight Ensemble’s first-in-class, orally active small molecule antagonists of Interleukin-17 (IL-17), a cytokine implicated in multiple inflammatory and autoimmune diseases, and present preclinical data on the oral efficacy and anti-inflammatory effects of the company’s IL-17A inhibitor Ensemblin.
comments powered by